# Medtronic to Post First Earnings Since MiniMed Spin-Off on November 24

> Medtronic reports fiscal 2027 second-quarter results on November 24, its first since spinning off MiniMed.

- Published: 2026-11-21T20:12:52+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-21/medtronic-first-earnings-after-minimed-spinoff
- Source: [The Motley Fool](https://www.fool.com/investing/2026/11/21/medtronic-is-about-to-report-its-first-earnings-since-spinning-off-minimed-should-you-buy-the-stock-before-nov-24/)

## Key takeaways

- Medtronic will report its first earnings since completing the MiniMed spin-off on October 15, 2026.
- Analysts expect Medtronic's revenue to rise 6% year over year in the quarter, with adjusted EPS down 2%.
- Medtronic expects fiscal 2027 revenue to rise 7.25%-7.75% after fiscal 2026 organic growth of 5.8%.
- MiniMed will report its fiscal 2027 second-quarter results on November 24, 2026.

Medtronic will report its first earnings since completing the spin-off of its diabetes unit, MiniMed, on November 24, 2026. [The Motley Fool](https://www.fool.com/investing/2026/11/21/medtronic-is-about-to-report-its-first-earnings-since-spinning-off-minimed-should-you-buy-the-stock-before-nov-24/) reported that analysts expect revenue to rise 6% year over year in the fiscal 2027 third quarter, while adjusted EPS is expected to dip 2%.

## Medtronic's First Report Without MiniMed

[Medtronic](https://akta.pro/company-profiles/000076n/medtronic) is a global medical technology company founded in 1949 that designs and sells devices across cardiovascular, surgical robotics, neurovascular and neuromodulation therapy areas, serving hospitals and healthcare systems in more than 150 countries. The company concluded the MiniMed spin-off on October 15, 2026, removing the diabetes business from its balance sheet.

Medtronic's earnings declined in fiscal 2023 and fiscal 2024, which ended in April 2024, as it dealt with supply chain constraints, inflation, forex headwinds, regulatory challenges for its diabetes business and a lumpy post-pandemic recovery in elective procedures. Earnings grew again in fiscal 2025 and fiscal 2026 as the company stabilized costs, expanded its cardiovascular and neuroscience businesses and spun off MiniMed. Revenue grew 5.8% organically in fiscal 2026, its strongest top-line growth in a decade, and Medtronic expects fiscal 2027 revenue to rise 7.25%-7.75%.

For the fiscal 2027 third quarter, the cardiovascular and neuroscience businesses should remain strong, according to The Motley Fool. The completion of the MiniMed spin-off, reinvestment in higher-growth platforms, early-stage manufacturing costs for newer cardiovascular devices and a few recent acquisitions are squeezing margins.

MiniMed, now a separate company, received FDA clearance for its tubeless insulin pump, MiniMed Fit, which offers up to seven days of wear and a 300-unit insulin capacity, Stock Titan reported. The pump includes SmartGuard automation and will launch in the U.S. pharmacy channel in spring 2027.

## Medtronic's Recent Deal and Revenue Figures

According to akta.pro [company records](https://akta.pro/company-data), Medtronic's full-year fiscal 2026 revenue was $36.364 billion, up 8.4% year over year and 5.8% on an organic basis, the highest annual revenue growth in 10 years. Fourth-quarter fiscal 2026 revenue was $9.807 billion, up 9.9% as reported and 6.6% organically, exceeding analyst consensus estimates by $200 million. The same records show Medtronic announced the acquisition of SPR Therapeutics for $650 million in May 2026 and acquired Scientia Vascular for $550 million plus a potential earn-out on June 12, 2026.

## Medtronic's Run-Up to the Report

Medtronic announced its intent to acquire Contego Medical for $380 million, expanding its carotid artery disease portfolio, Stock Titan reported in November 2026. The FDA approved two AI algorithms for Medtronic's implantable LINQ-II heart monitor on November 12, 2026, to support diagnosis of heart rhythm disorders, AD HOC NEWS reported. Medtronic reported fiscal 2026 second-quarter revenue of $9.756 billion, up 13.7% year over year, with cardiovascular, neuroscience and surgical portfolios all growing, Seeking Alpha reported in November 2026.

## MiniMed's November 24 Results

MiniMed will report its fiscal year 2027 second-quarter financial results on November 24, 2026, for the quarter ending October 30, 2026, PR Newswire reported. A news release with summary financial information is expected at 3:45 a.m. PST, followed by a webcast at 5:30 a.m. PST.

## Companies in this story

- [Medtronic company profile](https://akta.pro/company-profiles/000076n/medtronic) · website: https://www.medtronic.com
- [Minimed Group company profile](https://akta.pro/company-profiles/00stuia/minimed-group) · website: https://www.minimed.com

---
News for Agent · https://newsforagent.com/llms.txt
